New report published by Global QYResearch which offers insights on the global Calcitriol market. The Calcitriol market has been experiencing steady growth graph since past years. During the 2017-2025 timeline, the global market for Calcitriol is expected to reflect a 1.3x increase in the revenue growth. In 2017 the global Calcitriol market was valued at US$ 340 Mn and by the end of the assessment year (2025), it is estimated to touch a value more than US$ 450 Mn growing at a value CAGR of 3.5% throughout the period of forecast.
Global Calcitriol Market: Market Driver and Restraint
Applications of Calcitriol are anticipated to create new business segments in the market. Calcitriol is in use for a broad range of Osteoporosis products such as deficiency of Calcium treatment, health protection & others. The companies are focusing on launching products that are launched in few regions. There lies a great opportunity since only a few companies are into this business due to introductory stage of this product market. Calcitriol application is developed towards a more active mode.
Manufacturers are exploring the potential of Calcitriol in Renal Osteodystrophy. Application of Calcitriol in Psoriasis are gaining traction in the recent years. Recently, manufacturers have started using Calcitriol in the Other area. Further, there are also potential uses in the areas of Hemodialysis treatment.
Global Calcitriol Market: Key Takeaways
Global Calcitriol Market: Forecast by Nature
This segment includes Calcitriol Capsule, Calcitriol Solution, etc. In terms of volume, Calcitriol Capsule segment is expected to remain dominant in the global Calcitriol market.
Global Calcitriol Market: Forecast by Region
The largest producing area of Calcitriol are Europe, USA, India and China. China is the dominant market in the global Calcitriol market in terms of value. The China Calcitriol market was estimated to be valued at US$ 104.2 Mn in 2017 and is expected to expand at a value CAGR of 3.9% over the forecast period. The USA market is expected to expand at a robust rate of 3.8% in terms of revenue over the forecast period due to the steadily increasing production capacity for deficiency of Calcium treatment products in this region.
Global Calcitriol Market: Key Players
Roche, CP Pharmaceutical Group, Sun Pharmaceutical Industries, Teva, West Ward Pharmaceuticals, Cadila Pharmaceuticals, Strides Arcolab, Akorn, etc. are the key vendors included in this report.
The market concentration of Calcitriol is medium. The supply and demand relationship in the industry has been stable and modest. Of the 2017 global market, the top 5 companies, account for more than 40.00% of sales. The primary application of calcitriol is to treat osteoporosis and kidney diseases. Global osteoporosis drugs market is expected to experience notable growth owing to the increasing prevalence of osteoporosis coupled with rising geriatric population over the forecast period. Symptom of osteoporosis is not recognized in early stage, and is characterized by micro-architectural deterioration of bone tissues and low bone mass, leading to the bone fracture. Technologically advance treatment options coupled with increasing patient awareness levels, incidences of chronic diseases, lifestyle associated diseases are further anticipated to promote the growth of osteoporosis drug market. According to the report published by the W.H.O., about 22 million women and 5.5 million men in the Europe had osteoporosis in 2010 and in the United States about 8 million women and 2 million men had osteoporosis and is expected to grow notably in next two decades, which will further augment the growth of osteoporosis drug market over the forecast period. Drug classes include calcitonin, bisphosphonates, parathyroid hormone therapy (PTH), RANK Ligand Inhibitors (denosumab), selective estrogen receptor modulators (SERMs), and vitamin D calcium & estrogen therapy. The overall market was found to be dominated by generic products. As of 2014, biosulphonate was the largest and well established drug class for the treatment of osteoporosis. Introduction of new drug classes such as PTH and RANK ligand inhibitors are expected to drive the growth of osteoporosis drug market in upcoming years. Pipeline products such as romosozumab and odanacatib (cathepsin K inhibitor) awaiting the approval are expected to contribute to the major revenue share of the market over the forecast period.
Would like to place an order or any question, please feel free to contact at firstname.lastname@example.org | +44 20 3286 1546